183 related articles for article (PubMed ID: 36569886)
21. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.
Tsukimura T; Tayama Y; Shiga T; Hirai K; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2020 Dec; 25():100650. PubMed ID: 33072516
[TBL] [Abstract][Full Text] [Related]
22. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
23. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
24. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
25. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data.
Feriozzi S; Chimenti C; Reisin RC
Drug Des Devel Ther; 2024; 18():1083-1101. PubMed ID: 38585254
[TBL] [Abstract][Full Text] [Related]
26. Treatment switch in Fabry disease- a matter of dose?
Lenders M; Nordbeck P; Canaan-Kühl S; Kreul L; Duning T; Lorenz L; Pogoda C; Brand SM; Wanner C; Brand E
J Med Genet; 2021 May; 58(5):342-350. PubMed ID: 32522756
[TBL] [Abstract][Full Text] [Related]
27. A Fabry Disease Patient Who Developed Hypersensitivity Reaction against Agalsidase Beta following COVID-19 Infection.
Sonmez O; Ozcan SG; Trabulus S; Seyahi N
Nephron; 2023; 147(3-4):199-202. PubMed ID: 36174537
[TBL] [Abstract][Full Text] [Related]
28. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
29. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
30. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease.
Lenders M; Feidicker LM; Brand SM; Brand E
Front Immunol; 2023; 14():1266082. PubMed ID: 37818380
[TBL] [Abstract][Full Text] [Related]
31. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease.
Hwang S; Lee BH; Kim WS; Kim DS; Cheon CK; Lee CH; Choi Y; Choi JH; Kim JH; Yoo HW
Medicine (Baltimore); 2022 Sep; 101(37):e30345. PubMed ID: 36123934
[TBL] [Abstract][Full Text] [Related]
32. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
[TBL] [Abstract][Full Text] [Related]
33. Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
Lenders M; Stypmann J; Duning T; Schmitz B; Brand SM; Brand E
J Am Soc Nephrol; 2016 Jan; 27(1):256-64. PubMed ID: 25933799
[TBL] [Abstract][Full Text] [Related]
34. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
Schiffmann R; Goker-Alpan O; Holida M; Giraldo P; Barisoni L; Colvin RB; Jennette CJ; Maegawa G; Boyadjiev SA; Gonzalez D; Nicholls K; Tuffaha A; Atta MG; Rup B; Charney MR; Paz A; Szlaifer M; Alon S; Brill-Almon E; Chertkoff R; Hughes D
J Inherit Metab Dis; 2019 May; 42(3):534-544. PubMed ID: 30834538
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
36. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
38. Precision medicine in Fabry disease.
Lenders M; Brand E
Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
[TBL] [Abstract][Full Text] [Related]
39. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
40. Fabry Disease: The Current Treatment Landscape.
Lenders M; Brand E
Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
